Program for Autoimmune Disease Intervention (PADI)

Focus: 

To apply genetic and immunologic discoveries to benefit people with autoimmune diseases such type 1 diabetes, multiple sclerosis, and lupus

Anticipated Impact: 

Improved targeted therapies and enhanced ability to predict prognosis of autoimmune diseases, including type 1 diabetes, multiple sclerosis, and lupus

Abstract: 

The investigators will pioneer immunologic staging or profiling as a tool for early diagnosis, selection of treatment, monitoring of therapeutic response, and prediction of prognosis for Type 1 diabetes, MS, and lupus, diseases of particularly high prevalence in Washington State. By suppressing an immune response common to these three diseases, the investigators hope to improve basic diagnostic and treatment capabilities. Disease management in Type 1 diabetes, MS, and lupus can only be done with general immunosuppressive regimens that often create devastating side effects. Both regional and global markets are desperately in need of new therapeutic options for treating autoimmunity. Profiling will also be used to group those individuals eligible for clinical trials and therapies, create new therapeutic options, and generate economic development in Washington State for new biotechnology opportunities. The investigators will also expand outreach to physicians and people in Washington State who have Type 1 diabetes, MS and lupus to enhance access to innovative therapeutic clinical studies.

See also:

Multiple Sclerosis Management
Diabetes Screening and Management
Lupus Management

Grant Update

Principal Investigator:
Gerald Nepom
Grantee Organization:
Benaroya Research Institute
Grant Title:
Program for Autoimmune Disease Intervention (PADI)
Grant Cohort and Year:
2007 Innovative Programs to Advance Health Research (02)
Grant Period:
07/14/2008 - 07/13/2013 (Completed)
Grant Amount:
$5,521,085
The Program for Autoimmune Disease Intervention (PADI) has succeeded in several areas: 1. The enhanced BRI registries and repositories for people with MS, lupus, and T1D have enrolled more than 4,500 participants and provided samples for multiple translational research studies for analysis. Outcomes from these laboratory studies have included the identification of altered signaling pathways that are genetically controlled in these diseases, enabling us to develop biomarkers for studies of targeted therapeutics. Successful grant applications in these areas are continuing the work of the PADI program beyond the completion of LSDF funding. 2. In the area of therapeutics development, PADI studies led to the launch and capitalization of a new Seattle biotechnology company, and studies are ongoing between PADI investigators and the company to identify the appropriate patient population for initial clinical trials in lupus. Work continues in the PADI laboratories on next-generation therapeutics using preclinical models. 3. The Translational Research platform established in PADI with LSDF support has been successfully expanded through a major research collaboration with a multinational pharmaceutical company to continue beyond the completion of LSDF funding in 2013.

Impact in Washington

Location of LSDF Grantee
Locations of Collaborations/Areas of Impact
Seattle
Tacoma
Olympia
Vancouver
Wenatchee
Spokane
Bellingham
Everett
Yakima
Richland
Kirkland

Legislative Districts:
3, 4, 6, 8, 11, 12, 14, 17, 22, 27, 28, 29, 34, 36, 37, 38, 40, 42, 43, 45, 46, 49

Health Impacts

Multiple Sclerosis Management
Diabetes Screening and Management
Lupus Management